Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib PK with Rifabutin
NCT04470908Phase 1Completed
- Sponsor
- BeiGene
- Start
- Jul 2020
- Primary completion
- Nov 2020
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zanubrutinib in mantle cell lymphoma (MCL), Waldenstrom macroglobulinemia (WM), marginal zone lymphoma (MZL) and 2 more, sponsored by BeiGene. Primary endpoints: Area Under the Curve From Time Zero to Last Quantifiable Concentration at Day 11, Area Under the Curve From Time Zero to Infinity at Day 11 and 3 more. Started Jul 2020; status: completed.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)Waldenstrom macroglobulinemia (WM)marginal zone lymphoma (MZL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT04470908.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04470908.